Notice of Results

Avacta Group PLC
23 April 2024
 

 

 

 

 

 

23 April 2024

Avacta Group plc

 

("Avacta" or the "Company" and, together with its subsidiary undertakings, the "Group")

 

Notice of Results

 

Investor Presentation via Investor Meet Company

 

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, will announce its audited preliminary results for year ended 31st December 2023 ("FY23") on 30th April 2024.

 

Alastair Smith, Chief Executive Officer; Tony Gardiner, Chief Financial Officer; and Christina Coughlin MD, PhD, Head of Research and Development, will also deliver a live presentation via Investor Meet Company at 12:30 BST on the day.

 

The presentation is open to all existing and potential shareholders.

 

Investors can sign up to Investor Meet Company for free and add to meet AVACTA GROUP PLC via:

https://www.investormeetcompany.com/avacta-group-plc/register-investor. Investors who already follow Avacta on the Investor Meet Company platform will automatically be invited.

 

Questions can be submitted pre-event via the Investor Meet Company dashboard up until 29th April 09:00 BST, or at any time during the live presentation.

 

The Company will also post the results presentation on its website at the following page: https://avacta.com/investors/investor-resources/

 

-Ends-

 

For further information from Avacta Group plc, please contact:

 

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tony Gardiner, Chief Financial Officer

Michael Vinegrad, Group Communications Director

 

Tel: +44 (0) 1904 21 7070

www.avacta.com

 

Stifel Nicolaus Europe Limited (Nomad and Joint Broker)

Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Ben Good

 

 

Tel: +44 (0) 207 710 7600

www.stifel.com

Peel Hunt (Joint Broker)

James Steel / Chris Golden / Patrick Birkholm

Tel: +44 (0) 207 418 8900

www.peelhunt.com

 

ICR Consilium (Media and IR)

Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji

avacta@consilium-comms.com

 


 


 

 

 

 

About Avacta Group plc - https://www.avacta.com

 

Avacta Group is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics.

 

Avacta has two divisions focused on therapeutics and diagnostics.

 

Avacta Therapeutics: a clinical stage oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs.

 

Avacta Diagnostics: focused on supporting healthcare professionals and broadening access to diagnostics.

 

Avacta has two proprietary platforms, pre|CISION™ and Affimer®.

 

The pre|CISION™ platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumours compared with healthy tissues. The pre|CISION™ platform harnesses this tumour specific protease to activate pre|CISION™ peptide drug conjugates and pre|CISION™ antibody/Affimer® drug conjugates in the tumour microenvironment, reducing systemic exposure and toxicity, allowing dosing to be optimised to deliver the best outcomes for patients.

 

The lead pre|CISION™ programme AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies. It has shown a dramatic improvement in safety and tolerability in clinical trials to date compared with standard doxorubicin and preliminary signs of clinical activity in multiple patients.

 

 

To register for news alerts by email go to https://avacta.com/investors/investor-news-email-alerts/

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings